|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||-0.12|
|PE Ratio (TTM)||69.39|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...
NASDAQ INTERNATIONAL DESIGNATION: CLVLY) today announced its annual financial results for the year ended 30 June 2018, with the Group achieving its second consecutive profitable year. The Group concluded the year with $36.198m in cash and financial assets, with current liabilities of $3.470m.
Understanding Clinuvel Pharmaceuticals Limited’s (ASX:CUV) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
Clinuvel Pharmaceuticals Limited (ASX:CUV) is currently trading at a trailing P/E of 78.9x, which is higher than the industry average of 28x. While CUV might seem like a stock toRead More...
Clinuvel Pharmaceuticals Limited (ASX:CUV) delivered an ROE of 21.93% over the past 12 months, which is an impressive feat relative to its industry average of 17.87% during the same period.Read More...